Hepatocellular carcinoma in HIV positive patients

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 9, 2012, Pages 1257-1270

  Nunnari, G ^a,b   Berretta, M ^c   Pinzone, M R ^a   Di Rosa, M ^a   Berretta, S ^a   Cunsolo, G ^a   Malaguarnera, M ^a   Cosentino, S ^a   De Paoli, P ^d   Schnell, J M ^b   Cacopardo, B ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d National Center Institute   (Italy)

Author keywords

Co Infection; HAART; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; HIV; Liver transplant

Indexed keywords

BEVACIZUMAB; BOSUTINIB; NELFINAVIR; PLACEBO; SORAFENIB; TAMOXIFEN;

ABDOMINAL PAIN; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURGERY; CD4 LYMPHOCYTE COUNT; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; DISEASE DURATION; HEPATITIS B; HEPATITIS C; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MIXED INFECTION; NONHODGKIN LYMPHOMA; NONHUMAN; PREVALENCE; PRIMARY PREVENTION; RADIOFREQUENCY ABLATION; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SUBSTANCE ABUSE; SURVIVAL RATE; UTERINE CERVIX CANCER;

CARCINOMA, HEPATOCELLULAR; COINFECTION; HEPATITIS B; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84867972791     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (147)

1. NUNNARI G, LETO D, SULLIVAN J, XU Y, MEHLMAN KE, KULKOSKY J, POMERANTZ RJ. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses 2005; 21: 768-775.
2. NUNNARI G, SULLIVAN J, XU Y, NYIRJESY P, KULKOSKY J, CAVERT W, FRANK I, POMERANTZ RJ. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21: 714-718.
3. NUNNARI G, XU Y, ACHEAMPONG EA, FANG J, DANIEL R, ZHANG C, ZHANG H, MUKHTAR M, POMERANTZ RJ. Exogenous IL-7 induces Fas-Mediated human neuronal apoptosis: Potential effects during human immunodeficiency virus type 1 infection. J Neurovirol 2005; 11: 319-328.
4. NUNNARI G, POMERANTZ RJ. IL-7 as a potential therapy for HIV-1-Infected individuals. Expert Opin Biol Ther 2005; 5: 1421-1426.
5. BONNET F, LEWDEN C, MAY T, HERIPRET L, JOUGLA E, BEVILACQUA S, COSTAGLIOLA D, SALMON D, CHENE G, MORLAT P. Malignancy-Related causes of death in human immunodeficiency virus infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101: 317-324.
6. ZANET E, BERRETTA M, DI BENEDETTO F, TALAMINI R, BALLARIN R, NUNNARI G, BERRETTA S, RIDOLFO A, LLESHI A, ZANGHÌ A, CAPPELLANI A, TIRELLI U. Pancreatic Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Pancreas 2012 Jun 24. [Epub ahead of print]
7. DI BENEDETTO F, DI SANDRO S, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, BALLARIN R, COCCHI S, POTENZA L, LUPPI M, GERUNDA GE. Kaposi's sarcoma after liver transplantation. J Cancer Res Clin Oncol 2008; 134: 653-658.
8. MARTELLOTTA F, BERRETTA M, VACCHER E, SCHIOPPA O, ZANET E, TIRELLI U. AIDS-Related Kaposi's sarcoma: State of the art and therapeutic strategies. Curr HIV Res 2009; 7: 634-638.
9. ZUCCHETTO A, SULIGOI B, DE PAOLI A, PENNAZZA S, POLESE J, BRUZZONE S, REZZA G, DE PAOLI P, DAL MASO L, SERRAINO D. Excess mortality for non-AIDSdefining cancers among people with AIDS. Clin Infect Dis 2010; 51: 1099-1101.
10. SHIELS MS, COLE SR, KIRK GD, POOLE C. A metaanalysis of the incidence of non-AIDS cancers in HIV-Infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622.
11. BERRETTA M, CINELLI R, MARTELLOTTA F, SPINA M, VACCHER E, TIRELLI U. Therapeutic approaches to AIDSrelated malignancies. Oncogene 2003; 22: 6646-6659.
12. POLESEL J, FRANCESCHI S, SULIGOI B, CROCETTI E, FALCINI F, GUZZINATI S, VERCELLI M, ZANETTI R, TAGLIABUE G, RUSSO A, LUMINARI S, STRACCI F, DE LISI V, FERRETTI S, MANGONE L, BUDRONI M, LIMINA RM, PIFFER S, SERRAINO D, BELLÙ F, GIACOMIN A, DONATO A, MADEDDU A, VITARELLI S, FUSCO M, TESSANDORI R, TUMINO R, PISELLI P, DAL MASO L; CANCER AND AIDS REGISTRIES LINKAGE STUDY CANCER; AIDS REGISTRIES LINKAGE STUDY, LISE M, ZUCCHETTO A, DE PAOLI A, INTRIERI T, VATTIATO R, ZAMBON P, PUPPO A, PATRIARCA S, TITTARELLI A, AUTELITANO M, CIRILLI C, LA ROSA F, SGARGI P, DI FELICE E, CESARACCIO R, DONATO F, FRANCHINI S, ZANIER L, VITTADELLO F, VERCELLINO PC, SENATORE G, CONTRINO ML, ANTONINI S, PALOMBINO R, MASPERO S, LA ROSA MG, CAMONI L, REGINE V. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127: 1437-1445.
13. GALCERAN J, MARCOS-GRAGERA R, SOLER M, ROMAGUERA A, AMEIJIDE A, IZQUIERDO A, BORRÀS J, DE SANJOSÉ S, CASABONA J. Cancer incidence in AIDS patients in Catalonia, Spain. Eur J Cancer 2007; 43: 1085-1091.
14. NASTI G, MARTELLOTTA F, BERRETTA M, MENA M, FASAN M, DI PERRI G, TALAMINI R, PAGANO G, MONTRONI M, CINELLI R, VACCHER E, D'ARMINIO MONFORTE A, TIRELLI U; GICAT; ICONA. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-Related Kaposi sarcoma. Cancer 2003; 98: 2440-2446.
15. PANTANOWITZ L, SCHLECHT HP, DEZUBE BJ. The growing problem of non-AIDS-Defining malignancies in HIV. Curr Opin Oncol 2006; 18: 469-478.
16. BERRETTA M, LLESHI A, CAPPELLANI A, BEARZ A, SPINA M, TALAMINI R, CACOPARDO B, NUNNARI G, MONTESARCHIO V, IZZI I, LANZAFAME M, NASTI G, BASILE F, BERRETTA S, FISICHELLA R, SCHIANTARELLI C C, GARLASSI E, RIDOLFO A, GUELLA L, TIRELLI U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-222.
17. KULKOSKY J, BOUHAMDAN M, GEIST A, NUNNARI G, PHINNEY DG, POMERANTZ RJ. Pathogenesis of HIV-1 infection within bone marrow cells. Leuk Lymphoma 2000; 37: 497-515.
18. BONNET F, BURTY C, LEWDEN C, COSTAGLIOLA D, MAY T, BOUTELOUP V, ROSENTHAL E, JOUGLA E, CACOUB P, SALMON D, CHÉNE G, MORLAT P, AND AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HÉPATITES VIRALES EN19 MORTALITÉ STUDY GROUP AND THE MORTAVIC STUDY GROUP. Changes in cancer mortality among HIV-Infected patients: The mortalité 2005 survey. Clin Infect Dis 2009; 48: 633-639.
19. GILL J, MAY M, LEWDEN C, SAAG M, MUGAVERO M, REISS P, LEDERGERBER B, MOCROFT A, HARRIS R, FUX CA, JUSTICE A, COSTAGLIOLA D, CASABONA J, HOGG RS, KHAYKIN P, LAMPE F, VEHRESCHILD J, STERNE JA, GILL J, LEWDEN C, SAAG M, EGGER M, MUGAVERO M, REISS P, LEDERGERBER B, MOCROFT A, HARRIS R, MAY M, STERNE JA, BRODT HR, CASABONA J, CHENE G, COSTAGLIOLA D, DABIS F, MONFORTE AD, DE WOLF F, EGGER M, FATKENHEUER G, GILL J, GUEST J, HOGG RS, JUSTICE A, KIRK O, KITAHATA M, LAMPE F, LEDERGERBER B, REISS P, SAAG M, STERLING T, MAY M, HARRIS R, STERNE J. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
20. BEARZ A, VACCHER E, TALAMINI R, BERRETTA M, TIRELLI U. Comment on "Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection". Br J Cancer 2012; 106: 1899-1900.
21. NUNNARI G, COCO C, PINZONE MR, PAVONE P, BERRETTA M, DI ROSA M, SCHNELL M, CALABRESE G, CACOPARDO B. The role of micronutrients in the diet of HIV-1-Infected individuals. Front Biosci (Elite Ed) 2012; 4: 2442-2456.
22. GRULICH AE, VAN LEEUWEN MT, FALSTER MO, VAJDIC CM. Incidence of cancers in people with HIV/ AIDS compared with immunosuppressed transplant recipients: A meta-Analysis. Lancet 2007; 370: 59-67.
23. LIM ST, LEVINE AM. Non-AIDS-Defining cancers and HIV infection. Curr HIV/AIDS Rep 2005; 2(3): 146-153.
24. BURGI A, BRODINE S, WEGNER S, MILAZZO M, WALLACE MR, SPOONER K, BLAZES DL, AGAN BK, ARMSTRONG A, FRASER S, CRUM NF. Incidence and risk factors for the occurrence of non-AIDS defining cancer among human immunodeficiency virus infected individuals. Cancer 2005; 104: 1505-1511.
25. CLIFFORD GM, POLESEL J, RICKENBACH M, DAL MASO L, KEISER O, RAPITI E, LEVI F, JUNDT G, FISH T, BORDONI A, DE WECK D, FRANCESCHI S. Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
26. CRUM-CIANFLONE N, HULLSIEK KH, MARCONI V, WEINTROB A, GANESAN A, BARTHEL RV, FRASER S, AGAN BK, WEGNER S. Trends in the incidence of cancers among HIV-Infected persons and the impact of antiretroviral therapy: A 20-Year cohort study. AIDS 2009; 23: 41-50.
27. SILVERBERG MJ, CHAO C, LEYDEN WA, XU L, TANG B, HORBERG MA, KLEIN D, QUESENBERRY CP JR, TOWNER WJ, ABRAMS DI. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23: 2337-2345.
28. BURNS-NAAS LA, ZORBAS M, JESSEN B, EVERING W, STEVENS G, IVETT JL, RYAN TE, COOK JC, CAPEN CC, CHEN M, FURMAN G, THEISS JC, WEBBER S, WU E, SHETTY B, GASSER R, MCCLAIN RM. Increase in thyroid follicular cell tumor in nelfinavir-Treated rats observed in 2-Year carcinogenicity study is consistent with a rat-Specific mechanism of thyroid neoplasia. Hum Exp Toxicol 2005; 24: 643-654.
29. GIORDANO TP, KRAMER JR, SOUCHEK J, RICHARDSON P, EL-SERAG HB. Cirrhosis and hepatocellular carcinoma in HIV-Infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-2354.
30. SULKOWSKI MS, THOMAS DL, CHAISSON RE, MOORE RD. Hepatotoxicity associate with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
31. GOMAA AI, KHAN SA, TOLEDANO MB, WAKED I, TAYIORROBINSON SD. Hepatocellular carcinoma: Epidemiology, risk factors, and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308.
32. JONG-WOOK L. Global health improvement and WHO: Shaping the future. Lancet 2003; 362: 2083-2088.
33. PARKIN DM, PISANI P, FERLAY J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1990; 80: 827-841.
34. MONTALTO G, CERVELLO M, GIANNITRAPANI L, DANTONA F, TERRANOVA A, CASTAGNETTA LA. Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 13-20.
35. FERLAY J, PARKIN DM, PISANI P. Globocan Graphical Package 1: Cancer incidence and mortality worldwide. IARC Press, Lyon, 1998.
36. BOSCH FX, RIBES J, DIAZ M, CLERIES R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
37. EL-SERAG HB, MASON AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
38. PARIKH S, HYMAN D. Hepatocellular cancer: A guide for the internist. Am J Med 2007; 120: 194-202.
39. WEBER R, SABIN CA, FRIIS-MØLLER N, REISS P, EL-SADR WM, KIRK O, DABIS F, LAW MG, PRADIER C, DE WIT S, AKERLUND B, CALVO G, MONFORTE A, RICKENBACH M, LEDERGERBER B, PHIILIPS AN, LUNDGREN JD. Liver-Related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
40. MCGINNIS KA, FULTZ SL, SKANDERSON M, CONIGLIARO J, BRYANT K, JUSTICE AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: The roles of HIV, hepatitis C infection and alcohol abuse. J Clin Oncol 2006; 24: 5005-5009.
41. ROSENTHAL E, POIREE M, PRADIER C, PERRONNE C, SALMON-CERON D, GEFFRAY L, MYERS RP, MORLAT P, PIALOUX G, POI S, CACOUB P. Mortality due to hepatitis C-Related liver disease in HIV infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809.
42. SALMON-CERON D, ROSENTHAL E, LEWDEN C, BOUTELOUP V, MAY T, BURTY C, BONNET F, COSTAGLIOLA D, JOUGLA E, SEMAILLE C, MORLAT P, CACOUB P, CHÊNE G. The ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-Related causes of deaths in HIVinfected patients: The French national Mortalité 2005 study. J Hepatol 2009; 50: 736-745.
43. KRAMER JR, GIORDANO TP, SOUCHEK J, RICHARDSON P, HWANG LY, EL-SERAG HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.
44. MBULAITEYE SM, PARKIN DM, RABKIN CS. Epidemiology of AIDS-Related malignancies an international perspective. Hematol Oncol Clin North Am 2003; 17: 673-696.
45. BERAL V, NEWTON R. Overview of the epidemiology of immunodeficiency- Associated cancers. J Natl Cancer Inst Monogr 1998; 23: 1-6.
46. PUOTI M, BRUNO R, SORIANO V, DONATO F, GAETA GB, QUINZAN GP, PRECONE D, GELATTI U, ASENSI V, VACCHER E. Hepatocellular carcinoma in HIV-Infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-2293.
47. TRADATI F, COLOMBO M, MANNUCCI P, RUMI M, DE FAZIO C, GAMBA G, CIAVARELLA N, ROCINO A, MORFINI M, SCARAGGI A, TAIOLI E. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91: 1173-1177.
48. FULTZ S, JUSTICE A, BUTT A, RABENECK L, WEISSMAN S, RODRIGUEZ-BARRADAS M. Testing, referral and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with HIV infection. Clin Infect Dis 2003; 36: 1039-1046.
49. BRUNO R, PUOTI M, SACCHI P, FILICE C, CAROSI G, FILICE G. Management of hepatocellular carcinoma in human immunodeficiency virus-Infected patients. J Hepatol 2006; 44: S146-S150.
50. MACDONALD D, NELSON M, BOWER M, POWLES T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.World J Gastroenterol 2008; 14: 1657-1663.
51. SHERMAN KE, ROUSTER SD, CHUNG RT, RAJICIC N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: A crosssectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837.
52. BUFFET-JANVRESSE C, PEIGUE-LAFEUILLE H, BENICHOU J, VABRET A, BRANGER M, TRIMOULET P, GORIA O, LAURICHESSE H, ABBED A, VERDON R, BOUVET E, LAFON ME, DUSSAIX E, CORMERAIS L, DUPON M, HENQUELL C, JOSSE A, LAGOUTTE P, LARIVEN S, LEGAC S, RIACHI G, VERDON R, VITTECOQ D; HIV-HCV COHORT STUDY GROUP. HIV and HCV co-Infection: Situation at six French university hospitals in the year 2000. J Med Virol 2003; 69: 7-17.
53. THOMAS D. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36: S201-209.
54. KONOPNICKI D, MOCROFT A, DE WIT S, ANTUNES F, LEDERGERBER B, KATLAMA C, ZILMER K, VELLA S, KIRK O, LUNDGREN JD. EuroSIDA Group Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
55. ROCKSTROH JK, MOCROFT A, SORIANO V, TURAL C, LOSSO MH, HORBAN A, KIRK O, PHILLIPS A, LEDERGERBER B, LUNDGREN J. EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
56. DE LUCA A, BUGARINI R, COZZI LEPRI A, PUOTI M, GIRARDI E, ANTINORI A, POGGIO A, PAGANO G, TOSITTI G, CADEO G, MACOR A, TOTI M, D'ARMINIO MONFORTE A FOR THE I.CO.N.A. STUDY GROUP. Coinfection with hepatitis viruses and outcome of the first antiretroviral regimen in previously naive HIV-Infected subjects. Arch Intern Med 2002; 162: 2125-2132.
57. POLLICINO T, SQUADRITO G, CERENZIA G, CACCIOLA I, RAFFA G, CRAXI A, FARINATI F, MISSALE G, SMEDILE A, TIRIBELLI C, VILLA E, RAIMONDO G. Hepatitis B virus maintains its pro-Oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-110.
58. SHIOTA G, OYAMA K, UDAGAWA A, TANAKA K, NOMI T, KITAMURA A, TSUTSUMI A, NOGUCHI N, TAKANO Y, YASHIMA K, KISHIMOTO Y, SUOU T, KAWASAKI H. Occult hepatitis B virus infection in HBs antigen-Negative hepatocellular carcinoma in a Japanese population: Involvement of HBx and p53. J Med Virol 2000; 62: 151-158.
59. EL-SERAG HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37(2): S88-S94.
60. AHN J, FLAMM SL. Hepatocellular carcinoma. Dis Mon 2004; 50: 556-573.
61. LIU CJ, KAO JH. Hepatitis B virus-Related hepatocellular carcinoma: Epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007; 70: 141-145.
62. ARBUTHNOT P, CAPOVILLA A, KEW M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, miogenoactivated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000; 15: 357-368.
63. FUNG J, LAI CL, YUEN MF. Hepatitis B and C virusrelated carcinogenesis. Clin Microbiol Infect 2009; 15: 964-970.
64. KREMSDORF D, SOUSSAN P, PATERLINI-BRECHOT P, BRECHOT C. Hepatitis B virus-Related hepatocellular carcinoma: Paradigms for viral-Related human carcinogenesis. Oncogene 2006; 25: 3823-3833.
65. SATO S, FUJIYAMA S, TANAKA M, YAMASAKI K, KURAMOTO I, KAWANO S, SATO T, MIZUNO K, NONAKA S. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994; 21: 159-166.
66. NUNNARI G, SMITH JA, DANIEL R. HIV-1 Tat and AIDSassociated cancer: Targeting the cellular anti-Cancer barrier. J Exp Clin Cancer Res 2008; 27: 3.
67. CORALLINI A, ALTAVILLA G, POZZI L, BIGNOZZI F, NEGRINI M, RIMESSI P, GUALANDI F, BARBANTI BRODANO G. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993; 53: 5569-5575.
68. ALTAVILLA G, CAPUTO A, LANFREDI M, PIOLA C, BARBANTI-BRODANO G, CORALLINI A. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157: 1081-1089.
69. ZAULI G, GIBELLINI D, MILANI D, MAZZONI M, BORGATTI P, LA PLACA M, CAPITANI S. Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res 1993, 53: 4481-4485.
70. CAMPIONI D, CORALLINI A, ZAULI G, POSSATI L, ALTAVILLA G, BARBANTI, BRODANO G. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retroviruses 1995, 11: 1039-1048.
71. ENSOLI B, GENDELMAN R, MARKHAM P, FIORELLI V, COLOMBINI S, RAFFELD M, CAFARO A, CHANG HK, BRADY J, GALLO RC. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-680.
72. ALBINI A, BARILLARI G, BENELLI R, GALLO RC, ENSOLI B. Tat, the human immunodeficiency virus type regulatory protein, has angiogenic properties. Proc Natl Acad Sci USA 1995; 92: 4838-4842.
73. ENSOLI B, BARILLARI G, SALAHAUDIN ZS, GALLO RC, WONG-STAAL F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345: 84-86.
74. SCALA G, RUOCCO MR, AMBROSINO C, MALLARDO M, GIORDANO V, BALDASSARE F, DRAGONETTI E, QUINTO I, VENUTA S. The expression of the interleukin 6 gene induced by the human immunodeficiency virus type 1 Tat protein. J Exp Med 1994; 179: 961-971.
75. WESTENDORP MO, LI-WEBER M, FRANK RW, KRAMMER PH. Human immunodeficiency virus type 1 upregulates interleukin secretion in activated T cells. J Virol 1994; 68: 4177-4185.
76. DE MARCHI F, D'ADDA DI FAGAGNA F, FALASCHI A, GIACCA M. Activation of transcription factor NF-KB by the Tat protein of human immunodeficiency virus type-1. J Virol 1996; 70: 4427-4437.
77. DANTA M, SEMMO N, FABRIS P, BROWN D, PYBUS OG, SABIN CA, BHAGANI S, EMERY VC, DUSHEIKO GM, KLENERMAN P. Impact of HIV on host-Virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197: 1558-1566.
78. DANTA M, DUSHEIKO GM. Acute HCV in HIV-Positive individuals-A review. Curr Pharm Des 2008; 14: 1690-1697.
79. SMUKLER AJ, RATNER L. Hepatitis viruses and hepatocellular carcinoma in HIV-Infected patients. Curr Opin Oncol 2002; 14: 538-542.
80. BRUNO R, GAZZARUSO C, SACCHI P, ZOCCHETTI C, GIORDANETTI S, GARZANITI A, CIAPPINA V, MAFFEZZINI E, MASERATI R, FILICE G. High prevalence of metabolic syndrome among HIV-Infected patients: Link with the cardiovascular risk. J Acquir Immune Defic Syndr 2002; 31: 363-365.
81. GRAHAM CS, BADEN LR, YU E, MRUS JM, CARNIE J, HEEREN T, KOZIEL MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A metaanalysis. Clin Infect Dis 2001; 33: 562-569.
82. BENHAMOU Y, BOCHET M, DI MARTINO V, CHARLOTTE F, AZRIA F, COUTELLIER A, VIDAUD M, BRICAIRE F, OPOLON P, KATLAMA C, POYNARD T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
83. BRUNO R, GALASTRI S, SACCHI P, CIMA S, CALIGIURI A, DEFRANCO R, MILANI S, GESSANI S, FANTUZZI L, LIOTTA F, FROSALI F, ANTONUCCI G, PINZANI M, MARRA F. Gp120 modulates the biology of human hepatic stellate cells: A link between HIV infection and liver fibrogenesis. Gut 2010; 59(4): 513-520.
84. BABU CK, SUWANSRINON K, BREN GD, BADLEY AD, RIZZA SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS ONE 2009; 4: E4623.
85. BRAU N, LEAF HL, WIECZOREK RL, MARGOLIS DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 349: 924-925.
86. LLOVET JM, BUSTAMANTE J, CASTELLS A, VILANA R, AYUSO MDEL C, SALA M, BRÙ C, RODÈS J, BRUIX J. Natural history of untreated non surgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
87. EBARA M, OHTO M, SHINAGAWA T, SUGIURA N, KIMURA K, MATSUTANI S, MORITA M, SAISHO H, TSUCHIYA Y, OKUDA K. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986; 90: 289-298.
88. BARBARA L, BENZI G, GAIANI S, FUSCONI F, ZIRONI G, SIRINGO S, RIGAMONTI A, BARBARA C, GRIGIONI W, MAZZIOTTI A. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132-137.
89. OKAZAKI N, YOSHINO M, YOSHIDA T, SUZUKI M, MORIYAMA N, TAKAYASU K, MAKUUCHI M, YAMAZAKI S, HASEGAWA H, NOGUCHI M. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer 1989; 63: 2207-2210.
90. BENVEGNÙ L, NOVENTA F, BERNARDINELLO E, PONTISSO P, GATTA A, ALBERTI A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110-115.
91. DI BISCEGLIE AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13: S169-S171.
92. WEINIG M, HAKIM J, GUDZA I, TOBAIWA O. Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: A pilot study. Trans R Soc Trop Med Hyg 1997; 91: 570-572.
93. BRUNO R, SACCHI P, FILICE C, PUOTI M, FILICE G. Hepatocellular carcinoma in HIV-Infected patients with chronic hepatitis: An emerging issue. J Acquir Immune Defic Syndr 2002; 30: 535-536.
94. GARCIA-SAMANIEGO J, RODRIGUEZ M, BERENGUER J, RODRIGUEZ-ROSADO R, CARBO J, ASENSI V, SORIANO V. Hepatocellular carcinoma in HIV-Infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-183.
95. VIRIYAVEJAKUL P, ROJANASUNAN P, VIRIYAVEJAKUL A, PUNYARIT P, PUNPOOWONG B, KHACHANSAKSUMET V, RIGANTI M, PONGPONRATN E. Opportunistic infections in the liver of HIV-Infected patients in Thailand: A necropsy study. Southeast Asian J Trop Med Public Health 2000; 31: 663-667.
96. BRÄU N, FOX RK, XIAO P, MARKS K, NAGVI Z, TAYLOR LE, TRIKHA A, SHERMAN M, SULKOWSKI MS, DIETERICH DT, RIGSBY MO, WRIGHT TL, HERNANDEZ MD, JAIN MK, KHATRI GK, STERLING RK, BONACINI M, MARTYN CA, AYTAMAN A, LLOVET JM, BROWN ST, BINI EJ. Nor th American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV infected patients: A U.S.-Canadian multicenter study. J Hepatol 2007; 47: 527-537.
97. BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular carcinoma in HIV-Infected patients: Check early, treat hard. Oncologist 2011; 16: 1258-1269.
98. CARR BI. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 2004; 127: S218-S224.
99. MALAGUARNERA M, TROVATO G, RESTUCCIA S, GIUGNO I, FRANZÉ CM, RECEPUTO G, SICILIANO R, MOTTA M, TROVATO BA. Treatment of nonresectable hepatocellular carcinoma: Review of the literature and meta-Analysis. Adv Ther 1994; 11: 303-319.
100. RINGE B, PICHLMAYR R, WITTEKIND C, TUSCH G. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients.World J Surg 1991; 15: 270-285.
101. IWATSUKI S, STARZL TE, SHEAHAN DG, YOKOYAMA I, DEMETRIS AJ, TODO S, TZAKIS AG, VAN THIEL DH, CARR B, SELBY R. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221-229.
102. MAZZAFERRO V, REGALIA E, DOCI R, ANDREOLA S, PULVIRENTI A, BOZZETTI F, MONTALTO F, AMMATUNA M, MORABITO A, GENNARI L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
103. BRUIX J, SHERMAN M, LLOVET JM, BEAUGRAND M, LENCIONI R, BURROUGHS AK, CHRISTENSEN E, PAGLIARO L, COLOMBO M, RODES J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
104. LLOVET JM, DI BISCEGLIE AM, BRUIX J, KRAMER BS, LENCIONI R, ZHU AX, SHERMAN M, SCHWARTZ M, LOTZE M, TALWALKAR J, GORES GJ; PANEL OF EXPERTS IN HCC-DESIGN CLINICAL TRIALS. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
105. LLOVET JM, BURROUGHS A, BRUIX J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
106. VILLA E, FERRETTI I, GROTTOLA A, BUTTAFOCO P, BUONO MG, GIANNINI F, MANNO M, BERTANI H, DUGANI A, MANENTI F. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by varial oestrogen receptors. Br J Cancer 2001; 84: 881-885.
107. MAJNO PE, ADAM R, BISMUTH H, CASTAING D, ARICHE A, KRISSAT J, PERRIN H, AZOULAY D. Influence of preoperative transarterial lipiodol chemoembolization on resection or transplantation for and hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-703.
108. THOMAS MB. Systemic therapy for hepatocellular carcinoma. Cancer J 2008; 14: 123-127.
109. LLOVET JM, RICCI S, MAZZAFERRO V, HILGARD P, GANE E, BLANC JF, COSME A, SANTORO A, RAOUL JL, FORNER A, SCHWARTZ M, PORTA C, ZEUZEM S, BOLONDI L, GRETEN T, GALLE P, SEITZ JF, BORBATH I, HÄUSSINGER D, GIANNARIS T, SHAN M, MOSCOVICI M, VOLIOTIS D AND BRUIX J, FOR THE SHARP INVESTIGATORS STUDY GROUP. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
110. CHELIS L, NTINOS N, SOUFTAS V, DEFTEREOS S, XENIDIS N, CHAMALIDOU E, MALTEZOS E, KAKOLYRIS S. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report. Med Oncol 2010. (Epub ahead of print
111. PERBONI G, COSTA P, FIBBIA GC, MORANDINI B, SCALZINI A, TAGLIANI A, CENGARLE R, AITINI E. Sorafenib therapy for hepatocellular carcinoma in an HIVHCV coinfected patient: A case report. Oncologist 2010; 15: 142-145.
112. ZHU A, SAHANI D, DI TOMASO E, ANCUKIEWICZ M, CATALANO OA, SINDHWANI V, BLASZKOWSKY LS, YOON SS, LAHDENRANTA J, BHARGAVA P, MEYERHARDT J, CLARK JW, KWAK EL, HEZEL AF, MIKSAD R, ABRAMS TA, ENZINGER PC, FUCHS CS, RYAN DP, JAIN RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27: 3027-3035.
113. THOMAS MB, MORRIS JS, CHADHA R, IWASAKI M, KAUR H, LIN E, KASEB A, GLOVER K, DAVILA M, ABBRUZZESE J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
114. RIZELL M, ANDERSSON M, CAHLIN C, HAFSTRÖM L, OLAUSSON M, LINDNÉR P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008; 13: 66-70.
115. CASTELLS A, BRUIX J, BRÚ C, AYUSO C, ROCA M, BOIX L, VILANA R, RODÉS J. Treatment of hepatocellular carcinoma with tamoxifen: A double-Blind placebo-Controlled trial in 120 patients. Gastroenterology 1995; 109: 917-922.
116. LIU CL, FAN ST, NG IO, LO CM, POON RT, WONG J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study. Am J Gastroenterol 2000; 95: 218-222.
117. CHOW PK, TAI BC, TAN CK, MACHIN D, WIN KM, JOHNSON PJ, SOO KC; ASIAN-PACIFIC HEPATOCELLULAR CARCINOMA TRIALS GROUP. High-Dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36: 1221-1226.
118. NOWAK A, FINDLAY M, CULJAK G, STOCKLER M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004; 3: CD001024.
119. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, BALLARIN R, CODELUPPI M, GUARALDI G, GERUNDA GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34: 422-427.
120. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, QUINTINI C, CODELUPPI M, TIRELLI U, GERUNDA GE. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24: E26-27.
121. DI BENEDETTO F, DI SANDRO S, DE RUVO N, BERRETTA M, MONTALTI R, GUERRINI GP, BALLARIN R, DE BLASIIS MG, SPAGGIARI M, SMERIERI N, IEMMOLO RM, GUARALDI G, GERUNDA GE. Human immunodeficiency virus and liver transplantation: Our point of view. Transplant Proc 2008; 40: 1965-1971.
122. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, BALLARIN R, CODELUPPI M, GUARALDI G, GERUNDA GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34: 422-427.
123. KUMADA T, NAKANO S, TAKEDA I, SUGIYAMA K, OSADA T, KIRIYAMA S, SONE Y, TOYODA H, SHIMADA S, TAKAHASHI M, SASSA T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
124. DI BENEDETTO F, BERRETTA M, DE RUVO N, TARANTINO G, D'AMICO G, BALLARIN R, IEMMOLO RM, GERUNDA GE. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? J Surg Oncol 2012; 105: 111-112.
125. FRASSETTO LA, BROWNE M, CHENG A, WOLFE AR, ROLAND ME, STOCK PG, CARISON L, BENET LZ. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
126. TAVIO M, GROSSI P, BACCARANI U, SCUDELLER L, PEA F, BERRETTA M, ADANI G,VIVARELLI M, RIVA A, TIRELLI U, BRESADOLA V, VIALE P, RISALITI A. HIV-Infected patients and liver transplantation: Who, when and why. Curr HIV Res 2011; 9: 120-127.
127. MALAGUARNERA G, GIORDANO M, PALADINA I, BERRETTA M, CAPPELLANI A, MALAGUARNERA M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55: 2744-2755.
128. PRACHIALIAS AA, POZNIAK A, TAYLOR C, SRINIVASAN P, MUIESAN P, WENDON J, CRAMP M, WILLIAMS R, O'GRADY J, RELA M, HEATON ND. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72: 1684-1688.
129. POWLES T, BOWER M, DAUGAARD G, SHAMASH J, DE RUITER A, JOHNSON M, FISHER M, ANDERSON J, MANDALIA S, STEBBING J, NELSON M, GAZZARD B, OLIVER T. Multicenter study of human immunodeficiency virus-Related germ cell tumors. J Clin Oncol 2003; 21: 1922-1927.
130. HUGHES CA, SHAFRAN SD. Treatment of Hepatitis C in HIV-Coinfected patients. Ann Pharmacother 2006; 40: 479-489.
131. LABARGA P, SORIANO V, VISPO ME, PINILLA J, MARTIN-CARBONERO L, CASTELLARES C, CASADO R, MAIDA I, GARCIA-GASCO P, BARREIRO P. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-Infected patients. J Infect Dis 2007; 196: 670-676.
132. DE BONA A, GALLI L, GAILOTTA G, GUZZO A, ALAGNA L, LAZZARIN A, UBERTI-FOPPA C. Rate of cirrosis progression reduced in HIV/HCV co-Infected non-Responders to anti-HCV therapy. New Microbiol 2007; 30: 259-264.
133. SORIANO V, GARCIA-SAMANIEGO J, BRAVO R, GONZALEZ J, CASTRO A, CASTILLA J, MARTÍNEZ-ODRIOZOLA P, COLMENERO M, CARBALLO E, SUÁREZ D, RODRÍGUEZPIÑERO FJ, MORENO A, DEL ROMERO J, PEDREIRA J, GONZÁLEZ-LAHOZ J. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585-591.
134. LAGUNO M, MURILLAS J, BLANCO JL, MARTINEZ E, MIQUEL R, SANCHEZ-TAPIAS JM, BARGALLO X, GARCÍACRIADO A, DE LAZZARI E, LARROUSSE M, LEÓN A, LONCÁ M, MILINKOVIC A, GATELL JM, MALLOLAS J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-Infected patients. Aids 2004; 18: 27-36.
135. CHUNG RT, ANDERSEN J, VOLBERDING P, ROBBINS GK, LIU T, SHERMAN KE, PETERS
136. TORRIANI FJ, RODRIGUEZ-TORRES M, ROCKSTROH JK, LISSEN E, GONZALEZ-GARCIA J, LAZZARIN A, CAROSI G, SASADEUSZ J, KATLAMA C, MONTANER J, SETTE H JR, PASSE S, DE PAMPHILIS J, DUFF F, SCHRENK UM, DIETERICH DT; APRICOT STUDY GROUP. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-Infected patients. N Engl J Med 2004; 351: 438-450.
137. CARRAT F, BANI-SADR F, POL S, ROSENTHAL E, LUNELFABIANI F, BENZEKRI A, MORAND P, GOUJARD C, PIALOUX G, PIROTH L, SALMON-CÉRON D, DEGOTT C, CACOUB P, PERRONNE C; ANRS HCO2 RIBAVIC STUDY TEAM. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-Infected patients: A randomized controlled trial. JAMA 2004; 292: 2839-2848.
138. GHANY MG, STRADER DB, THOMAS DL, SEEFF LB; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-1374.
139. CHUNG RT. Hepatitis C and B viruses: The new opportunists in HIV infection. Top HIV Med 2006; 14: 78-83.
140. MOORE RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999; 29: 44-49.
141. ALVAREZ D, DIETERICH DT, BRAU N, MOOREHEAD L, BALL L, SULKOWSKI MS. Zidovudine use but not weight-Based ribavirin dosing impacts anaemia during HCV treatment in HIV-Infected persons. J Viral Hepat 2006; 13: 683-689.
142. HOGGARD PG, KEWN S, BARRY MG, KHOO SH, BACK DJ. Effects of drugs on 2',3'-Dideoxy-2',3'-Didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41: 1231-1236.
143. LAFEUILLADE A, HITTINGER G, CHADAPAUD S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
144. SALMON-CERON D, CHAUVELOT-MOACHON L, ABAD S, SILBERMANN B, SOGNI P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357: 1803-1804.
145. LIAW YF, SUNG JJ, CHOW WC, FARREIL G, LEE CZ, YUEN 11, TANWANDEE T, TAO QM, SHUE K, KEENE ON, DIXON JS, GRAY DF, SABBAT J; CIRRHOSIS ASIAN LAMIVUDINE MULTICENTRE STUDY GROUP. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 2004; 351: 1521-1531.
146. LOK AS, MCMAHON BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661-662.
147. GIACALONE A, SPINA M, BERRETTA M, TIRELLI U. Two types of fatigue in cancer patients. Br J Cancer 2012; 106: 424; author reply 425.